TFA Therapeutics (RAJAF) Non Operating Income (2020 - 2023)

TFA Therapeutics has reported Non Operating Income for 4 years, with the latest figure at -$37076.0 in Q4 2023.

• On a quarterly basis, Non Operating Income rose 51.6% year-over-year to -$37076.0 in Q4 2023; TTM through Dec 2023 was -$147433.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$13694.0, down 85.35% from the prior year.
• Non Operating Income was -$37076.0 for Q4 2023 at TFA Therapeutics, up from -$76609.0 in the prior quarter.
• The five-year high for Non Operating Income was -$13482.0 in Q4 2021, with the low at -$76609.0 in Q4 2022.
• Average Non Operating Income over 4 years is -$36858.2, with a median of -$28671.0 recorded in 2020.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income slumped 468.23% in 2022, then jumped 51.6% in 2023.
• Over 4 years, Non Operating Income stood at -$20266.0 in 2020, then jumped by 33.47% to -$13482.0 in 2021, then plunged by 468.23% to -$76609.0 in 2022, then surged by 51.6% to -$37076.0 in 2023.
• The last three Non Operating Income figures came in at -$37076.0 (Q4 2023), -$76609.0 (Q4 2022), and -$13482.0 (Q4 2021), per Business Quant data.